Back to list
Protein, peptide and antibody engineering · Antibody engineering

Single-domain and nanobody design

Model and optimise single-domain antibodies around framework features, long CDR3 loops, solubility and epitope accessibility.

Discuss your research question
Original scientific visual for Single-domain and nanobody design
01
OVERVIEW

What Single-domain and nanobody design is designed to address

Single-domain and nanobody design is not a one-score software run. It is a reviewable analysis path organised around “How can candidate single-domain antibodies balance epitope recognition, structural stability and developability?”, beginning with input quality, comparators and intended use of evidence before selecting an appropriate methodological level.

The work centres on Single-domain antibody modelling, Epitope docking and CDR analysis, Framework, solubility and mutation design and links Single-domain antibody sequences, Optional antigen structure and epitope, Species, framework and construct requirements directly to Structural and complex candidates, Sequence-optimisation suggestions, Experimental construct priorities. Reporting separates supporting evidence, conflicting signals, parameter dependence and conditions for follow-up validation.

How can candidate single-domain antibodies balance epitope recognition, structural stability and developability?

Suitable research settings

  • Projects that need to answer “How can candidate single-domain antibodies balance epitope recognition, structural stability and developability?”
  • Studies requiring consistent comparison and quality control across Single-domain antibody modelling and Epitope docking and CDR analysis
  • Teams that need Structural and complex candidates, Sequence-optimisation suggestions, Experimental construct priorities with complete reproduction records
02
SERVICE SCOPE

Analyses included in the service

Single-domain antibody modelling

Apply Single-domain antibody modelling to single-domain antibody sequences and produce structural and complex candidates. First confirm that single-domain antibody sequences can support the downstream analysis.

Epitope docking and CDR analysis

Apply Epitope docking and CDR analysis to optional antigen structure and epitope and produce sequence-optimisation suggestions. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.

Framework, solubility and mutation design

Apply Framework, solubility and mutation design to species, framework and construct requirements and produce experimental construct priorities. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.

03
METHOD SELECTION

Select the methodological level for the question

MethodBest suited toWatch for
Single-domain antibody modellingEstablishing the input baseline and initial search space for Single-domain and nanobody designErrors in Single-domain and nanobody design input state, structure or data definition propagate through later steps
Epitope docking and CDR analysisComparing candidate states, features or mechanisms in Single-domain and nanobody design to form prioritiesSingle-domain and nanobody design comparisons require consistent conditions; raw scores are not experimental measurements
Framework, solubility and mutation designReviewing key Single-domain and nanobody design results, interpreting differences and recording uncertaintyModels do not directly predict expression, aggregation, immunogenicity or in-vivo distribution; long-CDR3 uncertainty benefits from experimental restraints.
04
WORKFLOW

From question definition to reproducible delivery

  1. Frame the research question

    Use “How can candidate single-domain antibodies balance epitope recognition, structural stability and developability?” to define comparators, decision use, experimental context and the strength of evidence the computation can support.

  2. Review and curate inputs

    Review Single-domain antibody sequences, Optional antigen structure and epitope, Species, framework and construct requirements; resolve structure, naming, unit, batch or microstate issues and record any remaining assumptions.

  3. Design methods and controls

    Combine Single-domain antibody modelling, Epitope docking and CDR analysis, Framework, solubility and mutation design with controls, replicates, sensitivity checks or independent evidence, defining decision criteria before computation.

  4. Compute with quality control

    Run Single-domain and nanobody design, including Single-domain antibody modelling, in a reproducible environment; retain inputs, versions, parameters, logs and intermediate outputs, and flag convergence, sampling, data-quality and applicability issues.

  5. Interpret and deliver

    Organise Structural and complex candidates, Sequence-optimisation suggestions, Experimental construct priorities while separating direct observations, model inference and working hypotheses, then prioritise experiments or follow-up computation.

05
INPUTS & DELIVERABLES

What is needed and what is delivered

Inputs

  • Single-domain antibody sequences
  • Optional antigen structure and epitope
  • Species, framework and construct requirements

Optional supporting inputs

  • Known positive, negative or reference systems for basic expectation checks in Single-domain and nanobody design
  • Replicate experiments, external databases or literature evidence relevant to Single-domain and nanobody design
  • Timing, compute, software-compatibility or delivery-format constraints for Single-domain and nanobody design

Deliverables

  • Structural and complex candidates
  • Sequence-optimisation suggestions
  • Experimental construct priorities
06
QUALITY CONTROL

Quality control and interpretation limits

How results are reviewed

  • Single-domain and nanobody design: Preserve functional residues, sequence constraints and construct boundaries
  • Single-domain and nanobody design: Check structural confidence, interface geometry and conformational diversity
  • Single-domain and nanobody design: Compare with natural sequences, negative controls and alternative models
  • Single-domain and nanobody design: Keep expression, folding, affinity and function as experimental validation items

Boundaries that remain

  • Models do not directly predict expression, aggregation, immunogenicity or in-vivo distribution; long-CDR3 uncertainty benefits from experimental restraints.
  • Single-domain and nanobody design results apply only to the recorded inputs, parameters, models and sampling scope. Changes to input state, comparison conditions or project objectives may require new computation.
07
PROJECT PATTERNS

Common ways projects begin

From one system to comparable candidates

When single-domain antibody sequences are available but decision criteria are inconsistent, establish baselines and controls, then use Single-domain antibody modelling, Epitope docking and CDR analysis, Framework, solubility and mutation design to build candidate tiers and deliver structural and complex candidates with a difference analysis.

Independent review of existing results

When results relevant to Single-domain and nanobody design conflict, revisit single-domain antibody sequences and analytical assumptions around Single-domain antibody modelling, then add replicates, sensitivity checks or alternative models to distinguish signal from method conditions.

08
FAQ

Questions before a project begins

What is required before Single-domain and nanobody design begins?

The minimum inputs are Single-domain antibody sequences, Optional antigen structure and epitope, Species, framework and construct requirements. If information is incomplete, an input audit identifies which gaps change method selection and which can be handled as explicit assumptions.

Can the result directly prove “How can candidate single-domain antibodies balance epitope recognition, structural stability and developability?”?

No single model output should be treated as experimental fact. Models do not directly predict expression, aggregation, immunogenicity or in-vivo distribution; long-CDR3 uncertainty benefits from experimental restraints. Quality controls determine whether results support a priority or mechanism hypothesis; key conclusions still require appropriate experiments or independent data.

Which reusable files are delivered?

Typical delivery includes Structural and complex candidates, Sequence-optimisation suggestions, Experimental construct priorities, together with input-curation records, key parameters, software and database versions, quality-control results, editable figures and limitations. Exact raw formats are confirmed in the project plan.

START WITH THE QUESTION

Describe your research question and we will evaluate the right computational path

Start a project